IGF-1 LR3 vs MK-677: direct injection vs the GH-axis route

IGF-1 LR3 and MK-677 both raise IGF-1, which is why they get compared, but they do it through completely different routes and that route is the whole safety story.

MK-677 (ibutamoren) is an oral ghrelin mimetic. It tells your pituitary to release more growth hormone, which tells your liver to make more IGF-1. The rise is indirect, slow, and still buffered by your binding proteins, and your pituitary feedback loop stays in the circuit. Its metabolic cost is well-documented: fasting glucose and HbA1c drift up over weeks to months.

IGF-1 LR3 skips all of that. It is recombinant IGF-1 modified to resist its binding proteins, injected directly. There is no pituitary step, no IGFBP buffer, and no feedback brake on the injected dose. Free, bioactive IGF-1 hits receptors across the whole body, and because that includes the insulin-like glucose-lowering effect, the acute danger is hypoglycaemia rather than glucose creep.

The reason people compare them is the shared IGF-1 endpoint. The reason it matters which you pick is that LR3 is the harsher, less controllable, less forgiving way to get there.

Route: MK-677 is oral and works through the GH axis (pituitary to liver to IGF-1). LR3 is injected IGF-1 itself, bypassing the pituitary and liver entirely.

Feedback brake: MK-677's IGF-1 rise feeds back to the pituitary, which can throttle GH. LR3 has no brake on the injected dose; it actually suppresses your own GH and IGF-1 while it runs.

IGFBP buffering: MK-677-driven IGF-1 is over 99% bound and buffered. LR3 is engineered to escape the binding proteins, so it circulates free and bioactive, which intensifies both the anabolic signal and the hypoglycaemia risk per unit.

Glucose effect: MK-677 raises glucose slowly (fasting glucose 5.4 to 6.8 mmol/L in 4 weeks in one study; HbA1c +0.2% over 2 years). LR3 lowers glucose acutely and can cause hypoglycaemia that is harder to correct than insulin hypoglycaemia, then drives insulin resistance chronically.

Convenience: MK-677 is one pill daily. LR3 requires injections and tight timing around food to manage the glucose drop.

Monitoring: MK-677's IGF-1 reads cleanly on a standard assay. LR3 may cross-react with the IGF-1 assay, so its serum IGF-1 is hard to interpret, and an on-cycle HOMA-IR is artefactually low because LR3 suppresses insulin output.

Evidence: MK-677 has multiple human RCTs including a 2-year trial. LR3 has no human efficacy or safety trial in athletes; everything is extrapolated from animal data, mecasermin, and acromegaly.

MK-677 is the lower-risk way to raise IGF-1 if:

• You want IGF-1 elevation with oral convenience and no injections
• You accept a slow glucose creep and will monitor fasting glucose and HbA1c
• You have clean baseline metabolic markers
• You want a serum IGF-1 number you can actually interpret

IGF-1 LR3 is the more aggressive, higher-risk option if:

• You specifically want direct, IGFBP-resistant IGF-1 receptor stimulation
• You accept acute hypoglycaemia risk and the discipline of never dosing fasted
• You understand its serum IGF-1 and on-cycle insulin numbers are hard to interpret
• You accept there is no human safety data in athletes

On running them together: stacking them stacks MK-677's glucose creep onto LR3's hypoglycaemia and organ-growth pressure, and makes IGF-1 monitoring uninterpretable because MK-677 raises endogenous liver IGF-1 on top of the injected LR3 signal. There is little rationale for it.